RUNX2 and melanoma: As shown in Table 1, reduced levels of the receptor tyrosine kinases IGF-1R, FGFR1, PDGFRβ, and EGFR were detected in the RUNX2 knocked down 1205LU melanoma cells as compared with the non-silencing (control) ShRNA-expressing 1205LU cells.